InSilicoTrials

Today, we welcome a new member to InSilicoTrials—Paolo Messina!   Based in Saronno, Italy, Paolo joins us as a 𝗦𝘁𝗮𝘁𝗶𝘀𝘁𝗶𝗰𝗮𝗹 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿, 𝗥𝗪𝗗 & 𝗔𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝘀. With a background in biostatistics and experimental statistics, he is a highly skilled and experienced biostatistician. Having gained valuable expertise at two leading CROs, Paolo will undoubtedly be a great asset to our R&D Team and beyond.   This year, the InSilicoTrials team is growing more than ever, and we’re thrilled to welcome talented professionals like Paolo! #NewMember #TeamGrowing #RD #InSilicoTrials 

The #DeCODe project has opened a 𝗰𝗮𝗹𝗹 𝗳𝗼𝗿 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 to accelerate innovation in paediatric and orphan medical devices.   As a project partner, InSilicoTrials is proud to contribute its expertise in digital health innovation and regulatory guidance, helping developers leverage in silico technologies to streamline device assessment and compliance.   We encourage eligible innovators to apply and benefit from this valuable opportunity: https://lnkd.in/eYJj_WJG #MedicalInnovation #PaediatricDevices #RareDiseases #InSilicoTrials #EU4Health

Our COO, Mario Torchia, and BD Manager, Gizem Inak, will be attending the 𝗦𝗖𝗢𝗣𝗘 𝗦𝘂𝗺𝗺𝗶𝘁 𝟮𝟬𝟮𝟱, taking place from 𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆 𝟯-𝟲, 𝟮𝟬𝟮𝟱, in 𝗢𝗿𝗹𝗮𝗻𝗱𝗼, 𝗙𝗹𝗼𝗿𝗶𝗱𝗮!   This annual event focuses on clinical trial innovation, planning, management, and operations, featuring 30 different conferences, plenary keynote sessions, and numerous networking opportunities.   𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 InSilicoTrials! If you're attending, this is your chance to learn how we're revolutionizing the life sciences industry with in silico modeling and simulation solutions.   Join Mario or Gizem at SCOPE through the Cambridge Healthtech Institute's partnering platform to schedule a meeting.   More info about SCOPE here: https://lnkd.in/g9N7SgA   #SCOPE #ClinicalTrials #DigitalHealth #Innovation #InSilicoTrials

𝗛𝗼𝗻𝗼𝗿𝗲𝗱 𝘁𝗼 𝗯𝗲 𝗥𝗲𝗰𝗼𝗴𝗻𝗶𝘇𝗲𝗱 𝗶𝗻 𝘁𝗵𝗲 𝗛𝗦𝗕𝗖 𝟮𝟬𝟮𝟰 𝗔𝗻𝗻𝘂𝗮𝗹 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗥𝗲𝗽𝗼𝗿𝘁!   The report, authored by Jonathan Norris, Managing Director at HSBC Innovation Banking, highlights the evolving landscape of the venture capital market, with investors becoming more cautious and selective. This emphasizes the importance of innovative companies like InSilicoTrials, which are at the forefront of innovation in computational biology.   We are honored to be included in this report and recognized for our contributions to the Insight Platforms and Infrastructure (IPI) sub-sector, as highlighted on slide 40. This recognition underscores our commitment to developing cutting-edge technologies that are transforming drug discovery and development.   Download the report here: https://lnkd.in/ggqMVkCH   #HSBC #VentureCapital #ComputationalBiology #DrugDevelopment #IPI

Join our CEO, Luca Emili, and our VP Business Development, Sofia Stathopoulos at PMWC - Precision Medicine World Conference 2025, February 5-7, in Santa Clara, CA!   On February 7, our CEO will deliver a talk titled "𝗔𝗜 𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝘃𝗲 𝗺𝗼𝗱𝗲𝗹𝗶𝗻𝗴 𝗳𝗼𝗿 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁" during Track 2: AI Models for Research and Development, chaired by Gaddy Getz, Director of Cancer Genome Computational Analysis at the Broad Institute and Professor of Pathology at Harvard Medical School. The session will take place from 9:30 to 9:45 AM, right after Jensen Huang's talk, Founder and CEO of NVIDIA.   Luca's talk will focus on real-world applications of AI in accelerating drug discovery and how this technology can play a key role in drug development.   PMWC - Precision Medicine World Conference fosters global collaboration among leaders in genomics, AI, and personalized healthcare, featuring over 400 speakers, 90+ exhibitors, and a comprehensive 12-track agenda. Don't miss the opportunity to connect with our team, we're actively using the dedicated PMWC Partnering App as well!   Check out all the tracks here: https://lnkd.in/dSYEE-xZ   #PMWC #AI #PredictiveModeling #PrecisionMedicine #InSilicoTrials 

𝗟𝗮𝘀𝘁 𝘄𝗲𝗲𝗸, 𝗣𝗼𝘁𝘀𝗱𝗮𝗺 𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗶𝗻𝘃𝗶𝘁𝗲𝗱 Jane Knöchel, 𝗼𝘂𝗿 𝗻𝗲𝘄 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿, 𝘁𝗼 𝗽𝗿𝗲𝘀𝗲𝗻𝘁 𝗼𝗻 𝗲𝗻𝗵𝗮𝗻𝗰𝗶𝗻𝗴 𝗣𝗵𝗮𝘀𝗲 𝟯 𝗱𝗲𝘀𝗶𝗴𝗻 𝘄𝗶𝘁𝗵 𝗠𝗼𝗱𝗲𝗹-𝗜𝗻𝗳𝗼𝗿𝗺𝗲𝗱 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 (𝗠𝗜𝗗𝗗) 𝗮𝗻𝗱 𝗼𝗻 𝗹𝗲𝘃𝗲𝗿𝗮𝗴𝗶𝗻𝗴 𝗤𝘂𝗮𝗻𝘁𝗶𝘁𝗮𝘁𝗶𝘃𝗲 𝗦𝘆𝘀𝘁𝗲𝗺𝘀 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗹𝗼𝗴𝘆 (𝗤𝗦𝗣) 𝗺𝗼𝗱𝗲𝗹𝘀 𝗶𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁.   She showcased real-world examples demonstrating MIDD’s impact, sparking a lively and insightful discussion with PhD students from Potsdam University and Free University of Berlin. Optimizing the exposure-response relationship is crucial for regulatory submission, ensuring optimal dose selection for Phase 3 trials.   At InSilicoTrials, our platform seamlessly integrates MIDD with AI to accelerate drug development and improve patient lives—from preclinical development to market approval.   Want to see how we can help you innovate faster? Visit insilicotrials.com to book a demo and connect with us!   #PotsdamUniversity #MIDD #QSP #InSilicoTrials #DrugDevelopment #AI 

Last week, Luca Emili, Mario Torchia, Sofia Stathopoulos, and Walter Marchi attended the 𝟰𝟯𝗿𝗱 𝗔𝗻𝗻𝘂𝗮𝗹 𝗝.𝗣. 𝗠𝗼𝗿𝗴𝗮𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 in San Francisco. The week was a full of inspiring presentations, valuable connections with industry peers, and a forward-looking perspective on the future of healthcare. Here are some of the things that stood out to us the most: 🔹 𝗢𝗯𝗲𝘀𝗶𝘁𝘆 𝗮𝗻𝗱 𝗠𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝗛𝗲𝗮𝗹𝘁𝗵 emerged as a key focus, with significant discussion surrounding the success of GLP-1 drugs. J.P. Morgan Research predicts exponential growth for the GLP-1 market, exceeding $100 billion by 2030, driven by both diabetes and obesity treatments. At InSilicoTrials, we are committed to expanding our platform library with models specifically designed for obesity and metabolic health research, enabling our customers to conduct more efficient simulations. 🔹 𝗔𝗜 𝗶𝘀 𝗻𝗼 𝗹𝗼𝗻𝗴𝗲𝗿 𝗮 𝗳𝘂𝘁𝘂𝗿𝗶𝘀𝘁𝗶𝗰 𝗰𝗼𝗻𝗰𝗲𝗽𝘁, it is transforming drug discovery, diagnostics, and personalized medicine now! Our platform serves as a prime example of this. This year we look forward to providing more hands-on workshops, enabling participants to gain firsthand experience with its innovative features. 🔹 𝗪𝗼𝗺𝗲𝗻’𝘀 𝗛𝗲𝗮𝗹𝘁𝗵 & 𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗔𝗜 were top of mind at 𝗖𝗘𝗥𝗦𝗜 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗦𝘂𝗺𝗺𝗶𝘁. We look forward to continuing to support the FDA and other regulatory bodies in facilitating the rapid and safe advancement of medical product development, approval, and monitoring. We share the optimism of many others for a productive year ahead and look forward to participating in the conference again in 2026! #HealthcareInnovation #JPMHealthcareConference #MetabolicHealth #WomensHealth #FutureOfHealthcare #HealthTech

𝗜𝘁 𝘄𝗮𝘀 𝗮 𝗽𝗹𝗲𝗮𝘀𝘂𝗿𝗲 𝘁𝗼 𝗵𝗲𝗮𝗿 𝗗𝗿. 𝗝𝗶𝗹𝗹 𝗕𝗶𝗱𝗲𝗻 𝘀𝗽𝗲𝗮𝗸 𝗼𝗻 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗪𝗼𝗺𝗲𝗻'𝘀 𝗛𝗲𝗮𝗹𝘁𝗵 𝗮𝗻𝗱 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝘁 𝗙𝗶𝗲𝗿𝗰𝗲 𝗝𝗣𝗠𝗼𝗿𝗴𝗮𝗻. The White House Initiative on Women's Health Research aims to fundamentally change how the nation approaches and funds women's health research. It seeks to create a healthcare system that prioritizes women's health and addresses the gaps in research. As Dr. Biden highlighted, women's health research has been historically been underfunded. At InSilicoTrials, we're dedicated to accelerating women's health research through the power of in silico models. Our recent White Paper, 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗪𝗼𝗺𝗲𝗻’𝘀 𝗛𝗲𝗮𝗹𝘁𝗵𝘄𝗶𝘁𝗵 𝗜𝗻 𝗦𝗶𝗹𝗶𝗰𝗼 𝗗𝗲𝘀𝗶𝗴𝗻 𝗮𝗻𝗱 𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗦𝘁𝘂𝗱𝗶𝗲𝘀 delves into how these cutting-edge technologies can help address critical research gaps and improve women's health outcomes. Download it today to learn how we're making a difference: https://lnkd.in/eFXqpy7w #WomensHealth #Research #InSilicoTrials #Innovation

Maud Beneton 𝗶𝘀 𝗷𝗼𝗶𝗻𝗶𝗻𝗴 𝗜𝗻𝗦𝗶𝗹𝗶𝗰𝗼𝗧𝗿𝗶𝗮𝗹𝘀 𝘁𝗲𝗮𝗺 𝗮𝘀 𝗼𝘂𝗿 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗹𝗼𝗴𝘆! Based in France, Maud brings extensive expertise in Pharmacokinetics and Pharmacodynamics (PK/PD), Physiologically Based Pharmacokinetics, and Cross-Functional Project Management. With her strong team spirit, strategic mindset, and perseverance, Maud will play a key role in driving innovation and optimization in drug development. 𝗪𝗲’𝗿𝗲 𝗲𝘅𝗰𝗶𝘁𝗲𝗱 𝘁𝗼 𝗵𝗮𝘃𝗲 𝘆𝗼𝘂 𝗼𝗻 𝗯𝗼𝗮𝗿𝗱, 𝗠𝗮𝘂𝗱, 𝘄𝗲𝗹𝗰𝗼𝗺𝗲 𝘁𝗼 𝘁𝗵𝗲 𝘁𝗲𝗮𝗺! #NewTeamMember #Pharmacology #TeamGrowing #DrugDevelopment #InSilicoTrials

𝗠𝗲𝗲𝘁 𝗼𝘂𝗿 𝘁𝗲𝗮𝗺 𝗱𝘂𝗿𝗶𝗻𝗴 𝗝.𝗣. 𝗠𝗼𝗿𝗴𝗮𝗻 𝗪𝗲𝗲𝗸 𝗶𝗻 𝗦𝗮𝗻 𝗙𝗿𝗮𝗻𝗰𝗶𝘀𝗰𝗼, 𝗝𝗮𝗻𝘂𝗮𝗿𝘆 𝟭𝟮-𝟭𝟲, 𝟮𝟬𝟮𝟱! We're just days away until the start of the 𝗝.𝗣. 𝗠𝗼𝗿𝗴𝗮𝗻 𝗪𝗲𝗲𝗸, an amazing week to connect, share ideas, and a way to explore our in silico technologies that are considered to be the future of healthcare. Our leadership team will be there: CEO, Luca Emili; COO, Mario Torchia; VP of Business Development, Sofia Stathopoulos; and Corporate BD Manager, Walter Marchi. Don’t hesitate to reach out to set up a meeting with our colleagues. And, we will also be attending 𝗙𝗶𝗲𝗿𝗰𝗲 𝗝𝗣𝗠 𝗪𝗲𝗲𝗸, taking place from January 14-15. Curious about how our platform works? We’d love to connect. Contact us through the BIO Partnering System or reach out to us directly. #JPMorgan #SanFrancisco #HealthcareConference #InSilicoTrials #FierceJPMWeek